(Q24244248)

https://api.crossref.org/works/10.1002%2F14651858.CD005237

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

Negative symptoms in schizophrenia. Definition and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

New dimensions in the pharmacologic treatment of schizophrenia and related psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Chlorpromazine versus placebo for schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Molindone for schizophrenia and severe mental illness.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Haloperidol versus placebo for schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Aripiprazole for schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Issues in the meta-analysis of cluster randomized trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

The unit of analysis error in studies about physicians' patient care behavior

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Dropout rates in randomised antipsychotic drug trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Dropout rates with olanzapine or risperidone: a multi-centre observational study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Effects of neuroleptic medications on speech disorganization in schizophrenia: biasing associative networks towards meaning

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD005237

1 reference

7 January 2021

A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

The Efficacy of High-Dose Olanzapine Versus Clozapine in Treatment-Resistant Schizophrenia: A Double-Blind Crossover Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Systematic reviews in health care: Assessing the quality of controlled clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Elevation of prolactin levels by atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

A rating scale for drug-induced akathisia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Nithsdale schizophrenia surveys. 17. Fifteen year review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005237

7 January 2021

10.1002/14651858.CD005237

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4656746

OpenCitations bibliographic resource ID

4656746

1 reference